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Abstract
Botulinum neurotoxins (BoNTs) are extremely potent toxins that are capable of causing respiratory failure leading to long-
term intensive care or death. The best treatment for botulism includes serotype-specific antitoxins, which are most effective
when administered early in the course of the intoxication. Early confirmation of human exposure to any serotype of BoNT is
an important public health goal. In previous work, we focused on developing Endopep-MS, a mass spectrometry-based
endopeptidase method for detecting and differentiating the seven serotypes (BoNT/A-G) in buffer and BoNT/A, /B, /E, and /F
(the four serotypes that commonly affect humans) in clinical samples. We have previously reported the success of antibody-
capture to purify and concentrate BoNTs from complex matrices, such as clinical samples. However, to check for any one of
the four serotypes of BoNT/A, /B, /E, or /F, each sample is split into 4 aliquots, and tested for the specific serotypes
separately. The discovery of a unique monoclonal antibody that recognizes all four serotypes of BoNT/A, /B, /E and /F allows
us to perform simultaneous detection of all of them. When applied in conjunction with the Endopep-MS assay, the
detection limit for each serotype of BoNT with this multi-specific monoclonal antibody is similar to that obtained when
using other serotype-specific antibodies.
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Introduction
Botulinum neurotoxins (BoNTs) are protein neurotoxins pro-
duced by some species of the genus Clostridium, in particular,
Clostridium botulinum, C. butyricum, C. baratii, and C. argentinense.
Intoxication with any one of the seven serotypes of BoNT (A–G)
causes botulism, a disease that is naturally contracted by either
ingestion of food containing the toxin [1,2], colonization of the
bacteria in the gastrointestinal tract of infants or immunocompro-
mised individuals, inhalation of the toxin, or contact of the
bacterium with a wound [1]. Due to its extreme toxicity, global
availability, and ease of preparation, it is considered a likely agent
for bioterrorism [3]. The best therapeutic product for botulism
involves administration of therapeutic immunoglobulin which is
most effective when administered within 24 hr of exposure [1].
However, some currently commercially-available antitoxins are
serotype-specific, so those products will not protect or save a patient
if botulism is caused by any of the other serotypes. Therefore, the
earliest determination of any specific serotype exposure to BoNT is
critical before choosing the right antitoxin for treating a patient.
Previously, we reported the development of an assay for BoNT
detection and serotype differentiation termed the Endopep-MS
method [4–10]. This method detects all four BoNT serotypes
known to affect humans, BoNT/A, /B, /E, and /F. Briefly, this
method involves incubating BoNT with a peptide substrate that
mimics the natural target of BoNT. Each BoNT cleaves its peptide
substrate in a specific location, which is different for each of the
BoNT serotypes tested [2,4,6,9]. The reaction mixture is then
introduced into a mass spectrometer, which detects and accurately
reports the mass of any peptides within the mixture. Detecting the
peptide cleavage products corresponding to their specific toxin-
dependent location indicates the presence of a particular BoNT
serotype. Historically, mouse bioassays have been the most
commonly used method to detect BoNT [11], but as previously
demonstrated in several publications [4–6,9], the Endopep-MS
method can more rapidly detect BoNT at levels comparable to or
lower than levels detected with mouse bioassays.
As previously reported, Endopep-MS is highly effective in
identifying BoNT/A, /B, /E, and /F, the four serotypes that
commonly affect humans, in clinical samples. This method uses an
antibody affinity concentration/purification step prior to reacting
with the substrate [6–10]. Both polyclonal and monoclonal
antibodies to BoNT/A, /B, /E, and /F were evaluated for use
with the assay, and whenever possible, monoclonal antibodies
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were chosen in the assay due partly to their ability to recognize
specific epitopes on the toxin, ensuring that they recognize the
same epitopes with the same affinity during different test batches.
Polyclonal antibodies can also interfere with the enzymatic activity
of BoNT as measured by Endopep-MS [6,10], because Endopep-
MS detects the presence of BoNT specifically by measuring the
activity of the neurotoxin.
Because the antibodies used in the affinity concentration/
purification step are serotype-specific, in order to test for the
presence of four serotypes, a sample must either be split into four
aliquots or the same sample must be extracted four times, once
with each serotype-specific antibody. Neither of these steps is ideal,
since they negatively impact the assay in terms of sample volume
requirements or total analysis time used, as each extraction step is
approximately 1 hr. Therefore, the use of a single antibody which
can extract all four serotypes of BoNT at once would be beneficial
in an assay to rapidly detect BoNT. Here, we report the use
of a unique high-affinity monoclonal antibody, 4E17.1, in the
Endopep-MS assay for detection of all available subtypes of
BoNT/A, /B, /E, and /F. This multi-specific cross reactive
antibody allows for the simultaneous detection of BoNT/A, /B, /E,
and /F by Endopep-MS without requiring any additional time for
multiple toxin extractions, and it produces limits of detection which
are similar to those obtained with serotype-specific monoclonal
antibodies.
Materials and Methods
Ethics Statement
Studies using mice were conducted at USAMRIID, whose ethics
committee specifically approved this study. Studies were performed
under an approved IACUC protocol in compliance with the Animal
Welfare Act and other federal statutes and regulations relating to
animals and experiments involving animals, and adhere to principles
stated in the Guide for the Care and Use of Laboratory Animals,
National Research Council, 1996. The facility where this research
was conducted is fully accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care International.
Materials
Botulinum neurotoxin is very toxic and therefore requires
appropriate safety measures. All neurotoxins were handled
in a level 2 biosafety cabinet equipped with HEPA filters.
Commercially purified complex toxins BoNT/A1, BoNT/A2,
BoNT/B1, BoNT/C, BoNT/E3, protBoNT/F, and BoNT/G
were purchased from Metabiologics (Madison, WI). Tetanus
toxin (TeNT) was purchased from List Biological Laboratories,
Inc. (Campbell, CA). Tetanus toxin antibody (TetE3) was
purchased from Abcam (Cambridge, MA). Polyclonal rabbit
IgGs for BoNT/E and BoNT/F were purchased from
Metabiologics. Monoclonal antibodies CR2, RAZ1, and
B12.1 were provided by Professor James Marks of the
University of California, San Francisco. DynabeadsH Protein
G were purchased from Invitrogen (Carlsbad, CA) at 1.3 g/cm3
in phosphate buffered saline (PBS), pH 7.4, containing 0.1%
TweenH-20 and 0.02% sodium azide. Sequencing grade
modified trypsin at 0.5 mg/mL in 50 mM acetic acid was
purchased from Promega (Madison, WI). All chemicals were
from Sigma-Aldrich (St. Louis, MO) except where indicated.
Peptide substrates were synthesized by Los Alamos National
Laboratory (Los Alamos, NM, Table 1).
Preparation of 4E17.1 Antibodies
Monoclonal antibody (mAb) 4E17.1 was first selected and
engineered as a single chain fragment of variable domain (scFv)
antibody using yeast display technology. The original antibody
gene was selected from material of human volunteers immunized
with pentavalent BoNT toxoid using toxin of the BoNT/E3
subtype [12–15]. The scFv antibody was converted into full length
IgG by subcloning the V-gene into a human IgG1 expression
vector with IgG1/kappa constant regions and expressed in
Chinese Hamster Ovary cells. mAb 4E17.1 was purified to greater
than 90% homogeneity by protein G affinity chromatography
from the cell culture supernatant, and then buffer exchanged into
phosphate buffered saline (PBS) at a concentration of 1 mg/ml as
previously described [14–16].
Table 1. Amino acid sequence of peptides used in and produced by the Endopep-MS method.
Peptide Sequence m/z observed
BoNT/A substrate Biotin-KGSNRTRIDQGNQRATRXLGGK-Biotin 2878.7
BoNT/A NT product Biotin-KGSNRTRIDQGNQ 1699.9
BoNT/A CT product RATRXLGGK-Biotin 1197.8
BoNT/B substrate LSELDDRADALQAGASQFETSAAKLKRKYWWKNLK 4024.7
BoNT/B NT product LSELDDRADALQAGASQ 1759.9
BoNT/B CT product FETSAAKLKRKYWWKNLK 2283.4
BoNT/E substrate IIGNLRHMALDMGNEIDTQNRQIDRIMEKADSNKT 4041.1
BoNT/E NT product IIGNLRHMALDMGNEIDTQNRQIDR 2923.6
BoNT/E CT product IMEKADSNKT 1136.6
BoNT/D and /F substrate LQQTQAQVDEVVDIMRVNVDKVLERDQKLSELDDRADAL 4497.5
BoNT/D NT product LQQTQAQVDEVVDIMRVNVDKVLERDQK 3296.9
BoNT/D CT product LSELDDRADAL 1217.7
BoNT/F NT product LQQTQAQVDEVVDIMRVNVDKVLERDQ 3167.8
BoNT/F CT product KLSELDDRADAL 1345.2
The observed m/z of each peptide is also included.
doi:10.1371/journal.pone.0012237.t001
Single mAb Binds Multiple BoNT
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Epitiope Mapping of 4E17.1 Antibodies
As discussed in greater detail in work by Garcia-Rodriguez, et.al.
[17] and similar to work reported by Garcia-Rodriguez, et.al. [18]
and Levy, et.al. [19], yeast displayed BoNTHC, HN, and LC domains
were stained with 4E17.1 IgG. Because 4E17.1 was shown to bind
only to the HN domain, the HN sequences of the 7 BoNT serotypes
were aligned and inspected for regions which were conserved in
BoNT/A, /B, E, and F. 750–758 of BoNT/A was identified as
conserved between those serotypes. Single alanine mutants were
created for that region and displayed on the surface of yeast. The
affinity for 4E17.1 of those mutants was measured and residues Y750,
Y753, E756, and E757 within the translocation domain of BoNT/A
were found to play an important role in 4E17.1 binding.
Production of BoNT/A, /B, /D, /E, and /F culture
supernatants
Crude culture supernatants representing various BoNT/A, /B, /D,
/E, and /F subtypes (Table 2) were produced by incubating subcultures
of each strain for 5 days at 30–35uC. After centrifugation, supernatants
were removed and filtered through 0.22 mm filters. The filtered
supernatants were tested for upper limits of toxicity, which indicated
that the toxins were all present at concentrations of#10 mg/mL. Some
of the preparations were titered to determine lethality in mLD50/mL.
For toxin titrations, samples were diluted 2-fold in gelatin-
phosphate buffer (0.2% gelatin, 0.4% sodium phosphate), pH 6.2.
Female Crl:CD-1 mice, 16–22 g on receipt (Charles River
Laboratories, Raleigh, NC) were injected i.p. with total volumes of
0.1 mL diluted toxin. Mice were observed for 5 days, survivors were
tallied, and the results were analyzed using probit analysis (SPSS,
Chicago, IL). The final LD50/mL of the preparation was calculated
by dividing the initial dilution used in the assays by the probit result.
Titrations were done in duplicate and averaged to obtain the working
titers for each toxin. Duplicate titrations were also done on
commercially obtained toxins (Metabiologics, Madison, WI; Wako
Biologicals, Richmond, VA) using their stated toxicity as the initial
dilution, and the titers were averaged to obtain their working titer.
Table 2. Sequence alignment of known BoNT subtypes in the range of Y750 to E757 of BoNT/A.
Toxin Strain Accession # Amino acid sequence KD (pM)
BoNT/A1 Hall AF488749 Y N Q Y T E E E 1.83
BoNT/A2 CDC 1436 EF028393 Y N Q Y T E E E 7.98
BoNT/A3 Loch Maree DQ185900 Y N Q Y T E E E 4.5
BoNT/A4 Strain 657 EU341407 Y N Q Y T E E E ND
BoNT/A5 H0 4402 065 EU679004 Y N Q Y T E E E ND
BoNT/B1 Okra AB232927 Y N I Y S E K E 43760
BoNT/B2 213B (ATCC 7949) EF028395 Y N I Y S E K E 41330
BoNT/B3 CDC 795 EF028400 Y N I Y S E K E ND
BoNT/B4 Eklund 17B EF051570 Y N I Y S E E E 16.52
BoNT/B5 Strain 657 EF033130 Y N I Y S E K E 45210
BoNT/B6 Osaka05 AB302852 Y N I Y S E K E ND
BoNT/C Stockholm X62389 Y K K Y S G S D NB
BoNT/D CB-16 S49407 Y K K Y S G S D NB
BoNT/E1 German sprats (Hazen 35396) AB082519 Y N S Y T L E E 730
BoNT/E2 CDC 5247 EF028404 Y N S Y T L E E 205
BoNT/E3 Alaska E43 EF028403 Y N S Y T L E E 241
BoNT/E4 BL5262 AB088207 Y N S Y T L E E 260
BoNT/E5 LCL155 AB037704 Y N S Y T L E E ND
BoNT/E6 K35 AM695752 Y N S Y T L E E ND
BoNT/F1 Langeland GU213203 Y N N Y T S D E 65080
BoNT/F2 Strain 84 Y13631 Y N N Y T S D E ND
BoNT/F3 CDC 54086 GU213218 Y N N Y T S D E ND
BoNT/F4 CDC 54078 GU213214 Y N S Y T S D E ND
BoNT/F5 CDC 54074 GU213211 Y N N Y T S D E ND
BoNT/F6 Eklund 202F M92906 Y N N Y T S D E ND
BoNT/F7 Sullivan HM746656 Y N N Y T L D E ND
BoNT/G 113/30 X74162 Y N R Y S E E D ND
TeNT CN3911 (Harvard) X06214 Y K I Y S G P D ND
Residues that play an important role in 4E17.1 binding are bolded and underlined. Dissociation rates (KD) in pM of BoNT with mAb 4E17.1 are also listed. NB indicates no
binding was observed and ND indicates that the KD was not determined. Each BoNT is also identified by strain tested where appropriate. Equilibrium dissociation
constant (KD) were measured by flow fluorimetry in a KinExA [17].
doi:10.1371/journal.pone.0012237.t002
Single mAb Binds Multiple BoNT
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Neurotoxin Extraction
Monoclonal antibody 4E17.1 was immobilized and crosslinked to
the DynabeadsH Protein G as described in the manufacturer’s
protocol using 40 mg of antibody diluted into 500 mL of PBS for every
100 m L of DynabeadsH Protein G. Cross-linked IgG-coated
DynabeadsH were stored in PBS-Tween buffer (PBS with 0.05%
TweenH-20) at 4uC for up to 12 weeks. For the BoNT extraction
assay, an aliquot of 20 mL of antibody-coated beads was mixed for
1 hr with a solution of 5–100 mL of each culture supernatant, which is
mixed with 495 mL of phosphate buffered saline with 0.01% Tween
(PBST) buffer. After mixing for 1 hr with constant agitation at room
temperature, the beads were washed twice in 1 mL each of PBST
and then washed once in 100 mL of water. For limit of detection tests,
BoNT at varying levels was spiked into an aliquot of 500 mL of PBST.
Negative controls consisted of PBST with no spiked toxin extracted
using the above protocol. For TeNT work, 5 mg of TeNT was spiked
into 50 mL of PBST with the remainder of the extraction protocol as
above. For simultaneous multiple serotype BoNT detection,
100 mLD50 of BoNT/A, /B, /E, and /F were spiked into 500 mL
of serum mixed with 50 mL of 106PBST.
Endopep-MS reaction
The reaction was performed as previously described [4–10] with
a few modifications. In all cases, the final reaction volume was
20 mL; the final concentration of the reaction buffer was 0.05 M
Hepes (pH 7.3), 25 mM dithiothreitol, 20 mM ZnCl2, and 1 mg/
mL bovine serum albumin; and the final concentration of the
peptide substrate was 50 pmol/mL, with peptide sequences listed
in Table 1. All samples were incubated at 37uC for 4 hrs.
MS Detection of Endopep-MS reaction
A 2 mL aliquot of each reaction supernatant was mixed with
18 mL of matrix solution consisting of alpha-cyano-4-hydroxy
cinnamic acid (CHCA) at 5 mg/mL in 50% acetonitrile, 0.1%
trifluoroacetic acid (TFA), and 1 mM ammonium citrate. A 0.5 mL
aliquot of the resulting milieu was pipeted onto a 192-spot matrix-
assisted laser desorption/ionization (MALDI) plate (Applied
Biosystems, Framingham, MA). Mass spectra of each spot were
obtained by scanning from 1100 to 4800 m/z in MS-positive ion
reflector mode on an Applied Biosystems 4800 Proteomics Analyzer
(Framingham, MA). The instrument used a Nd-YAG laser at
355 nm, and each spectrum was an average of 2400 laser shots.
Tryptic Digest and Mass Spectrometric Analysis of TeNT
Following bead extraction of spiked TeNT from PBST buffer,
the beads were reconstituted in 10 mL of 50 mM ammonium
bicarbonate, pH=7.5 and 2 mL of stock trypsin. 2 mL of 500 mM
ammonium bicarbonate, pH=7.5 and 2 mL of stock trypsin were
also added to 20 mL of the extraction supernatant. These mixtures
were digested overnight at 37uC. Following digestion, 1 mL of 10%
TFA was added to both mixtures. The supernatant was then
removed from the beads for analysis. 5 mL of this supernatant and
the extraction supernatant mixture were analyzed by LC-MS/MS
for amino acid sequence as reported by Kalb, et.al. [7].
Results
Monoclonal Antibody 4E17.1 Binds Multiple Subtypes of
BoNT/A
Monoclonal antibody (mAb) 4E17.1 interacts with residues
Y750, Y753, E756, and E757 within the translocation domain of
BoNT [17]. A sequence alignment (Table 2) of the five currently-
recognized subtypes of BoNT/A shows that all subtypes contain
these same residues; therefore, mAb 4E17.1 should theoretically
bind all known subtypes of BoNT/A. Protein G beads were coated
with mAb 4E17.1 and used to extract toxins of BoNT/A1, /A2,
/A3, and /A4 from individual culture supernatants.
Figure 1 includes the mass spectra obtained from the reactions
of the extracted BoNT/A toxins. In the presence of BoNT/A, the
peptide substrate at m/z 2878.7 is cleaved by the toxin to produce
peaks at m/z 1197.8 and 1699.9 (identities listed in Table 1).
Hence, peaks at 1197.8 and 1699.9 are evidence for the presence
of BoNT/A, as BoNT/A1, /A2, /A3, and /A4 are all known to
cleave this peptide substrate [9]. The mass spectra in Figures 1A–
1D all contain peaks at m/z 1197.8 and 1699.9 and therefore those
reactions contain BoNT/A toxin. Figure 1E is a negative control
of blank culture supernatant medium that does not contain toxin;
therefore there are no peaks at m/z 1197.8 and 1699.9. These
spectra illustrate that the affinity of mAb 4E17.1 for BoNT/A1,
/A2, /A3, or /A4 is sufficient for the effective extraction and
detection of all BoNT/A subtypes via Endopep-MS.
Monoclonal Antibody 4E17.1 Binds Multiple Subtypes of
BoNT/B, /E, and /F
After determining that mAb 4E17.1 could be used successfully
to extract and detect all subtypes tested of BoNT/A via Endopep-
MS, we investigated the use of this antibody to detect BoNT/B as
well. The sequences of BoNT/B subtypes within the 4E17.1
epitope are listed in Table 2 and indicate that for most subtypes, 3
of the 4 amino acids essential for 4E17.1 binding (Y750, Y753, and
E757) are present. BoNT/B4 contains all 4 amino acids essential
for binding; Y750, Y753, E756, and E757.
Figure 2 shows the mass spectra obtained from the reactions of
the extracted BoNT/B toxins with mAb 4E17.1. The peptide
substrate at m/z 4024.7 is cleaved by BoNT/B to produce peaks at
m/z 1759.9 and 2283.4 (identities listed in Table 1), and BoNT
/B1, /B2, /B4, and /B5 are all known to cleave this peptide
substrate [9]. Similar to the procedures used for BoNT/A
extraction, BoNT/B1, /B2, /B3, /B4, and /B5 were extracted
separately with beads coated with mAb 4E17.1, and peptide
substrate in reaction buffer was added to those beads. The mass
spectra in Figures 2A–2E all contain peaks at m/z 1759.9 and
2283.4, indicating that those reactions contained active BoNT/B
toxin. Figure 2F is a negative control of blank culture supernatant
medium which does not contain toxin; therefore there are no
peaks at m/z 1759.9 and 2283.4. These spectra demonstrate that
monoclonal antibody 4E17.1 has adequate affinity for BoNT/B1,
/B2, /B3, /B4, and /B5 for this antibody to be used to extract and
detect BoNT/B via Endopep-MS. Additionally, this is the first
report of BoNT/B3 detection with Endopep-MS.
Because the amino acid sequences of all BoNT/E subtypes
contain all four amino acids necessary for optimum 4E17.1
binding, it was expected that the 4E17.1 antibody should be able
to bind and extract all BoNT/E subtypes. Beads coated with
4E17.1 were therefore used to extract BoNT/E subtypes from
culture supernatant media. Figure 3 provides the mass spectra
obtained from the reaction of extracted BoNT/E1, /E2, /E3, and
/E4 with the peptide substrate at m/z 4041.1. This peptide is
cleaved by BoNT/E to produce cleavage products at m/z 1136.6
and 2923.6 (identities listed in Table 1), and subtypes BoNT/E1,
/E2, /E3, and /E4 are all known to cleave this peptide substrate
[9]. The mass spectra in figures 3A–3D all contain peaks at m/z
1136.6 and 2923.6, and therefore all contain BoNT/E toxin. The
negative control in 3E does not contain BoNT/E toxin; hence, the
peaks at m/z 1136.6 and 2923.6 are absent. These spectra
illustrate that the 4E17.1 antibody can be utilized to extract
BoNT/E1, /E2, /E3, and /E4 for detection via Endopep-MS.
Single mAb Binds Multiple BoNT
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The amino acid sequences of the 7 BoNT/F subtypes contain
Y750, Y753, and E757, three of the four amino acids determined
to be important in 4E17.1 binding. The BoNT/B subtypes also
contain these three amino acids, and it has already been shown
that the BoNT/B subtypes recognize 4E17.1, so it was expected
that the four subtypes of BoNT/F would also recognize 4E17.1.
Figure 4 shows the mass spectra from the reaction of extracted
BoNT/F1 (4A), BoNT/F6 (4B), and BoNT/F2 (4C) with the
peptide substrate at m/z 4497.5. These subtypes of BoNT/F
cleave this peptide substrate into cleavage products at m/z 1345.2
and 3167.8 (identities listed in Table 1), and those cleavage
products are present in Figures 4A–4C, proving that the 4E17.1
antibody can be used to extract those BoNT/F subtypes and
detect them via Endopep-MS. Figure 4D is the spectrum of blank
culture supernatant medium extracted with the 4E17.1 antibody.
It does not contain the cleavage products at m/z 1345.3 or 3167.8.
BoNT/F from C. baratii (BoNT/F7) also binds this antibody, but
requires a different peptide substrate to detect the toxin via its
activity and will be addressed in a separate publication.
Monoclonal Antibody 4E17.1 Does Not Bind BoNT/C and
/D Effectively
BoNT/C and /D both contain Y750 and Y753, but not E756
or E757 (Table 2). Similar to the procedures used for BoNT/A or
BoNT/B extraction, mAb 4E17.1 was used to extract BoNT/C
and /D, and the BoNT bead extracts were tested for activity via
Endopep-MS. Toxin levels below 20,000 mouse LD50 (mLD50) of
BoNT/C and 2,000 mLD50 of BoNT/D did not yield any positive
results by mass spectrometry, indicating that the toxin’s activity is
either inhibited by the 4E17.1 antibody or that the antibody is
inefficient at toxin extraction. As a comparison, samples
containing less than 1 mLD50 of BoNT/A, /B, /E, or /F were
positive following extraction with monoclonal antibody 4E17.1.
The dissociation rate (KD) for binding of 4E17.1 to BoNT/C and
/D [17] was so poor that it could not be measured (Table 2). This
effects the ability of this antibody to effectively bind BoNT/C or
/D, making it inefficient at toxin extraction.
Figure 5A shows a mass spectrum of 2000 mLD50 of BoNT/D
with no antibody extraction. Peaks at m/z 1217.7 and 3296.9
(identities listed in Table 1) indicate the presence of BoNT/D in a
sample. The substrate at m/z 4497.5 is not visible as it has been
completely consumed by the toxin. This is contrasted with
Figure 5B, which is the mass spectrum of 2000 mLD50 of
BoNT/D extracted with beads coated with monoclonal antibody
4E17.1. The cleavage products at m/z 1217.7 and 3296.9 are both
visible in this spectrum, but the dominant peak in this spectrum is
the singly-charged substrate at m/z 4497.5 and the doubly-charged
substrate peak at m/z 2249.1. Conversion of the substrate to the
cleavage products is vastly diminished in this spectrum as
compared to the spectrum in Figure 5A. This is due to the lower
level of toxin in the sample as most of the toxin remains behind
following extraction.
Additionally, some of this toxin activity can be explained by
non-specific binding of the toxin to the beads. This is illustrated in
Figure 5C, which is the mass spectrum of 2000 mLD50 of BoNT/
D extracted with beads coated with monoclonal antibody CR2, an
antibody specific for BoNT/A, but not cross reactive with BoNT/
D. One cleavage product at m/z 1217.7 is visible in this spectrum,
but the dominant peaks in this spectrum are the singly-charged
and doubly-charged substrate peaks at m/z 4497.5 and 2249.1
respectively. Presence of the cleavage product at m/z 1217.7
indicates the presence of a low level of BoNT/D on the beads due
to non-specific binding of the toxin to the beads.
Monoclonal Antibody 4E17.1 Does Not Bind BoNT/G and
Tetanus Toxin
Tetanus toxin (TeNT) contains Y750 and Y753, but not E756
or E757 (Table 2). BoNT/G contains Y750, Y753, and E756, but
not E757. Similar to the procedures for BoNT/A extraction,
mAb 4E17.1 was used to extract BoNT/G, and the BoNT bead
Figure 1. Mass spectra of the Endopep-MS BoNT/A reactions
with /A1 (1A), /A2 (1B), /A3 (1C), /A4 (1D), or no toxin (1E)
extracted using the 4E17.1 antibody-coated beads. The peptide
cleavage products indicating BoNT/A are m/z 1197.8 and 1699.9; the
peptide substrate is present at m/z 2878.7.
doi:10.1371/journal.pone.0012237.g001
Single mAb Binds Multiple BoNT
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12237
extracts were tested for activity via Endopep-MS. This did not
yield any positive result by mass spectrometry, indicating that the
antibody is inefficient at toxin extraction. We have not developed
a peptide-based activity assay for TeNT, and we therefore could
not test for the activity of TeNT upon a peptide substrate as
evidence for its binding to monoclonal antibody 4E17.1.
Therefore, beads coated with monoclonal antibody 4E17.1 or
with a commercially-available monoclonal antibody to tetanus
toxin were used to extract TeNT. The beads were then digested
with trypsin and the tryptic fragments were analyzed by LC-MS/
MS.
There were several peptides which originated from TeNT in the
digest of the beads which used anti-TeNT for extraction, but these
peptides were not present in the digested beads which used anti-
4E17.1 for extraction (data not shown). Furthermore, a digest of
the supernatant consisting of material left behind after the
extraction of TeNT with 4E17.1 coated beads demonstrated that
TeNT remained behind in solution following extraction with
4E17.1 coated beads (data not shown).
Monoclonal Antibody 4E17.1 Binds Different BoNT
Serotypes Simultaneously
Monoclonal antibody 4E17.1 has been shown to bind separately
multiple subtypes of BoNT/A, /B, /E, and /F; therefore, it was
assumed that this antibody could bind multiple subtypes of BoNT/
A, /B, /E, and /F simultaneously. Beads coated with 4E17.1
antibody were used to extract BoNT/A, /B, /E, and /F spiked
into a single sample. The beads were then added to reaction buffer
with the four peptide substrates used to detect BoNT/A, /B, /E,
and /F. Figure 6A shows the mass spectrum from that reaction.
Peaks at m/z 1197.8 and 1699.9 indicate the presence of BoNT/A;
1759.9 and 2283.4 are markers for BoNT/B; 1136.6 and 2923.6
for BoNT/E; and 1345.2 and 3167.8 indicate BoNT/F, and the
identities of all cleavage products are listed in Table 1. The
presence of all these peaks demonstrates that monoclonal antibody
4E17.1 can be used to extract BoNT/A, /B, /E, and /F from a
single sample and that all four serotypes can be detected at once.
Although the toxins were present in an equimolar ratio in this
case, we also experimented with each individual toxin present at
levels up to 1000 times the others. Those results (data not shown)
indicate that we can still detect all four toxins in that case.
Additionally, serotype specific antibodies were also used to extract
BoNT/A, /B, /E, and /F spiked into serum, and those results are
depicted in Figures 6B, 6C, 6D, and 6E. These results demonstrate
that all four serotypes of BoNT can be detected individually using
4 times the sample volume.
Under natural conditions, it is unlikely that a single sample
would contain four serotypes of BoNT; however, there are some
cases when a single sample contains more than one serotype.
Several bivalent strains exist, known as A2b, Ba4, Af, and Bf, in
which the bacterium produces more than one serotype of BoNT
under certain conditions. Figure 7 shows that monoclonal
antibody 4E17.1 can be used to detect these bivalent strains, as
they are the mass spectra acquired from the reaction of peptide
substrates with 4E17.1 coated beads used to extract A2b (7A),
Ba4 (7B), Af (7C), and Bf (7D). In Figure 7A, peaks at m/z 1197.8
and 1699.9 illustrate the presence of BoNT/A, and the peak at
m/z 1759.9 indicates BoNT/B. In Figure 7B, the peak at m/z
1197.8 shows BoNT/A, and peaks at m/z 1759.9 and 2283.4
result from BoNT/B activity. In Figure 7C, the peak at m/z
1197.8 indicates BoNT/A, whereas the peak at m/z 1345.3
indicates BoNT/F. In Figure 7D, peaks at m/z 1759.9 and
2283.4 indicate BoNT/B, and the peak at m/z 1345.2 results
from BoNT/F activity.
Figure 2. Mass spectra of the Endopep-MS BoNT/B reactions with /B1 (2A), /B2 (2B), /B3 (2C), /B4 (2D), /B5 (2E), or no toxin (2F)
extracted using the 4E17.1 antibody-coated beads. The peptide cleavage products indicating BoNT/B are m/z 1759.9 and 2283.4 and the
peptide substrate is present at m/z 4024.7.
doi:10.1371/journal.pone.0012237.g002
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Limit of Detection of BoNT with Monoclonal Antibody
4E17.1 in Endopep-MS
The Endopep-MS assay detects BoNT via its activity, and it
uses antibody extraction to isolate and concentrate the toxin prior
to analysis. Some antibodies inhibit the enzymatic activity of the
toxin and therefore increase the limit of detection (LOD) of BoNT.
We therefore wanted to determine the LOD of BoNT/A, BoNT/
B, BoNT/E, and BoNT/F using mAb 4E17.1 for extraction of
those toxins from buffer. Using commercially-available, mouse-
titered BoNT/A, /B, /E, and /F, we determined that the LOD of
those toxins spiked into 0.5 mL of PBST buffer are 1 mLD50 for
BoNT/A, 0.05 mLD50 of BoNT/B, 0.1 mLD50 of BoNT/E, and
0.05 mLD50 of BoNT/F. These LOD are equivalent to those
obtained with other serotype-specific antibodies used for toxin
extraction, with the exception of BoNT/A, and the LOD in serum
and milk are the same as in PBST buffer. The LOD of BoNT/A
using a combination of the RAZ1 and CR2 antibodies engineered
for high affinity to BoNT/A is 0.5 mLD50.
Discussion
The different serotypes of BoNT are defined by their ability to
be neutralized by specific antitoxins; therefore, it is unusual for one
antibody to bind multiple serotypes of botulinum neurotoxin.
Figure 3. Mass spectra of the Endopep-MS BoNT/E reactions
with /E1 (3A), /E2 (3B), /E3 (3C), /E4 (3D), or no toxin (3E)
extracted using the 4E17.1 antibody-coated beads. The peptide
cleavage products indicating BoNT/E arem/z 1136.6 and 2923.6 and the
peptide substrate is present at m/z 4041.1.
doi:10.1371/journal.pone.0012237.g003
Figure 4. Mass spectra of the Endopep-MS BoNT/F reactions
with /F1 (4A), /F6 (4B), /F2 (4C), or no toxin (4D) extracted using
the 4E17.1 antibody-coated beads. The peptide cleavage products
indicating BoNT/F are m/z 1345.2 and 3167.8 and the peptide substrate
is present at m/z 4497.5.
doi:10.1371/journal.pone.0012237.g004
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Monoclonal antibody 4E17.1 binds the translocation domain of
BoNT, and residues Y750, Y753, E756, and E757 of BoNT/A
play important roles in antibody binding. These residues are fairly
well conserved among all of the known botulinum neurotoxins;
hence, a single monoclonal antibody could bind most of the known
botulinum neurotoxins at the same epitopic location.
All currently known subtypes of BoNT/A contain residues
Y750, Y753, E756, and E757. BoNT/A1-/A4 were tested for
their ability to bind monoclonal antibody 4E17.1. To test for the
presence or absence of the extracted toxin on the antibody-coated
beads, we used Endopep-MS. BoNT/A1-/A4 were all efficiently
extracted from buffer with antibody 4E17.1, and the beads from
those extractions all demonstrated the presence of active BoNT/A,
meaning that all four of those BoNT/A subtypes bind the 4E17.1
antibody. Although BoNT/A5 was unavailable for testing, it is
expected that this serotype will also effectively interact with 4E17.1
on the basis of its amino acid sequence (Y750, Y753, E756, and
E757) [20]. In fact, the amino acid sequence YNQYTEEE is
identical in 63 BoNT/A strains.
Most subtypes of BoNT/B contain three of the four key amino
acids in 4E17.1 binding; the exception to this is BoNT/B4, which
contains all four amino acids. Five of the currently known
subtypes of BoNT/B were available for testing, and all interacted
with the 4E17.1 antibody. This interaction indicates that E756 is
perhaps not as critical for binding as the other amino acids. E756
is a lysine in most of the BoNT/B serotypes, and a mutation from
glutamic acid to lysine is not a conserved mutation. This non-
conserved mutation may be responsible for the higher KD
associated with BoNT/B in general for this antibody (Table 2)
[17]. Although BoNT/B6 was unavailable for testing, it is also
expected to interact with 4E17.1 based on its amino acid
sequence (Y750, Y753, K756, and E757) [21]. As with BoNT/A,
this epitope is highly conserved among 64 BoNT/B strains as
YNIYSEKE.
All currently known subtypes of BoNT/E contain all four key
amino acids in 4E17.1 binding. Subtypes BoNT/E1–E4 were
available for testing, and all four interacted with 4E17.1.
Subtypes BoNT/E5 and /E6 were unavailable for testing, but
based on the amino acid homology [22–23], both are expected
to interact with 4E17.1. Additionally, the examination of 55
BoNT/E strains demonstrates that this epitope is identical as
YNSYTLEE. All currently known subtypes of BoNT/F contain
Y750, Y753, and E757, three of the four key amino acids in
4E17.1 binding. Four of the seven subtypes were available for
testing, and all four interacted with 4E17.1. This is further
evidence that E756 is perhaps not as critical for binding as the
other residues, because E756 is an aspartic acid, a conserved
mutation, in all serotypes of BoNT/F. Subtypes BoNT/F3, /F4,
and /F5 were unavailable for testing, but based on the amino
acid homology [24], all are expected to interact with 4E17.1.
Furthermore, 60 strains of BoNT/F have this identical epitope
YNNYTSDE.
BoNT/C, /D, /G, and TeNT all contain Y750 and Y753, two
of the amino acids known to be important in 4E17.1 binding.
However, upon testing, it was determined that these toxins do not
efficiently interact with the 4E17.1 antibody. Hence, these data
show that a minimum of three of the four critical amino acids,
Y750, Y753, and E757, are required for efficient binding.
Furthermore, BoNT/G contains three of the four key amino
acids in 4E17.1 binding including Y750, Y753 and E756, but it
does not contain E757 and BoNT/G does not interact with
4E17.1. These additional data show that E756 is not critical for
4E17.1 interactions but that Y750, Y753, and especially E757 are
required for efficient binding.
Endopep-MS was developed to detect the presence of BoNT in
a clinical or food sample. An antibody affinity concentration/
purification step prior to reaction with the substrate is critical to
the success of the method when testing complex matrices such as
serum or stool extracts. Prior to the discovery of the 4E17.1
antibody, a sample needed to either be split into 4 aliquots or
extracted 4 separate times to test for the presence of four
serotypes of BoNT. Either option negatively affected the
Endopep-MS assay in terms of either sample volume require-
ments or time as each extraction step is approximately 1 hr.
Therefore, the development of a single antibody which can be
used to extract four serotypes of BoNT simultaneously, especially
the four serotypes commonly involved in human botulism, is
beneficial in the Endopep-MS assay to detect BoNT and would
be beneficial in other assays which use antibody-affinity for
BoNT detection.
We have tested the 4E17.1 antibody with spiked clinical and
food samples such as serum, stool extracts, and milk and found
that this antibody is particularly effective with serum and milk. For
stool extracts with a severe protease composition, we have had
recent success with 2M sodium chloride washes to remove
excessive proteases from the antibody-coated beads (manuscript
in preparation). In the presence of such extreme conditions,
Figure 5. Mass spectra of the Endopep-MS BoNT/D reactions
with no antibody extraction (5A), extraction with monoclonal
antibody 4E17.1 (5B), or extraction with monoclonal antibody
CR2 (5C). The peptide cleavage products indicating BoNT/D are m/z
1217.7 and 3296.9 and the peptide substrate is present at m/z 4497.5.
doi:10.1371/journal.pone.0012237.g005
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BoNT/B and /F in particular unfortunately are removed from the
antibody-coated beads, due to the higher dissociation rates [17]
listed in Table 2. Thus, the use of the 4E17.1 antibody may be
limited to stool extract samples which contain fewer proteases,
such as infant stools. Further studies employing real-world clinical
specimens are planned when such samples become available to
us. Nevertheless, as the LOD of BoNT/A, /B, /E, and /F are
equivalent or near equivalent to those obtained with other
serotype-specific antibodies used for toxin extraction, this new
antibody offers the opportunity to test for any of those toxin types
in an unknown sample.
The opinions, interpretations and recommendations are those
of the authors and are not necessarily those of the Centers for
Disease Control and Prevention or the US Army.
Figure 6. Mass spectrum of the Endopep-MS reaction of the simultaneous extraction of BoNT/A, /B, /E, and /F with monoclonal
antibody 4E17.1 (6A) or the single extraction of BoNT/A (6B), /B(6C), /E (6D), or /F (6E) with serotype-specific antibodies. Cleavage
products indicating those four BoNTs are marked.
doi:10.1371/journal.pone.0012237.g006
Figure 7. Mass spectra from the reaction of peptide substrates with 4E17.1 coated beads used to extract A2b (7A), Ba4 (7B), Af (7C),
and Bf (7D). Peaks at m/z 1197.8 and 1699.9 indicate BoNT/A, peaks at m/z 1759.9 and 2283.4 indicate BoNT/B, and peaks at m/z 1345.2 and 3167.8
result from BoNT/F activity.
doi:10.1371/journal.pone.0012237.g007
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